Connection
Rangaswamy Govindarajan to Follow-Up Studies
This is a "connection" page, showing publications Rangaswamy Govindarajan has written about Follow-Up Studies.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.212 |
|
|
|
-
Govindarajan R, Gujja S, Siegel ER, Batra A, Saeed A, Lai K, James JD, Fogel BJ, Williamson S. Programmed Cell Death-Ligand 1 (PD-L1) Expression in Anal Cancer. Am J Clin Oncol. 2018 07; 41(7):638-642.
Score: 0.107
-
Govindarajan R, Siegel E, Makhoul I, Williamson S. Bevacizumab and erlotinib in previously untreated inoperable and metastatic hepatocellular carcinoma. Am J Clin Oncol. 2013 Jun; 36(3):254-7.
Score: 0.076
-
Van Tine BA, Govindarajan R, Attia S, Somaiah N, Barker SS, Shahir A, Barrett E, Lee P, Wacheck V, Ramage SC, Tap WD. Incidence and Management of Olaratumab Infusion-Related Reactions. J Oncol Pract. 2019 11; 15(11):e925-e933.
Score: 0.029